NCT06839989View on ClinicalTrials.gov

An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC

PHASE2RecruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Mpox (Monkeypox)

Interventions

BIOLOGICAL

Mpox vaccination with MVA-BN

All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.

Trial Locations (1)

Unknown

RECRUITING

Centre Hospitalier Kabinda, Kinshasa

All Listed Sponsors

collaborator

MSF Médecins Sans Frontières Belgium

UNKNOWN

collaborator

Institut National pour la Recherche Biomedicale (INRB)

UNKNOWN

lead

Institute of Tropical Medicine, Belgium

OTHER

NCT06839989 - An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC | Biotech Hunter | Biotech Hunter